First human trial tests experimental pill for Tough-to-Treat cancers

NCT ID NCT07179081

Summary

This is an early-stage study testing a new oral medication called AL58805 in patients with advanced solid tumors that have stopped responding to standard treatments. Researchers will give increasing doses to 40 participants to find the highest safe amount and see how the body processes the drug. The main goal is to understand the medication's safety profile and identify any side effects before testing whether it can help control cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, 410013, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.